Company intelligence / Profile preview
Kancera
Stockholm, Swedenkancera.com ↗
- Ownership
- Public · KAN
- Development stage
- Other
01
Overview
Kancera has advanced its lead candidate, KAND567, from preclinical to clinical development. Over 150 healthy subjects and patients have been treated with KAND567. The drug has completed three phase I studies and two phase IIa studies. Currently, it is being studied in the combined phase Ib/IIa KANDOVA study for ovarian cancer. The second-generation candidate, KAND145, offers improved product properties and shares the same mechanism of action as KAND567
- Therapeutic areas
- OncologyImmunology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Kancera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kancera.